FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?

Invasive functional measurement of intermediate lesions has become the gold standard to define revascularization. Due to its favorable long-term prognostic value, fractional flow reserve (FFR) is the reference used to compare all others.

FFR e iFR discordantes hasta en un 20% de los casos ¿con cuál decidimos?

Recently, new nonhyperemic indexes, measured in a specific diastolic period, have emerged. Among them, the one with the most accumulated evidence is instantaneous wave-free ratio (iFR), which is just as helpful as FFR when it comes to decision-making, while being more practical and faster.

When FFR and iFR results match, revascularization is already decided. However, in up to 20% of cases there is a discordance in measurements, leaving the operator with a dilemma.

Multiple studies have compared angiography with FFR, and FFR vs. iFR.

Results from FAME, FAME 2, and DEFER showed a clinical benefit of using FFR vs. angiography for revascularization guidance, as well as the safety of deferring these lesions when their measurement was negative.


Read also: TCT 2020 | Crushed Prasugrel Administration prior PCI.


The DEFINE-FLAIR and iFR-SWEDEHEART trials showed noninferiority of iFR vs. FFR for lesion revascularization or deferral.

All of this evidence was compiled in the 2018 European guidelines, which provided a class IA recommendation for both indexes.

Clinical practice pushed iFR because it is faster to measure, cheaper, and presents fewer adenosine adverse events.


Read also: TCT 2020 | Surprising Differences in Stroke between SAPIEN 3 and Evolut R.


However, FFR and iFR equivalence has been challenged because of the frequent incidence of discordant results.

The 3V FFR-FRIENDS study, recently published in JAHA, compared nonhyperemic indexes vs. FFR at 5 years. This follow-up length seems very reasonable to finally answer these questions about FFR and iFR.

The analysis included 1024 vessels in 435 patients who were measured by FFR and nonhyperemic indexes, such as iFR.


Read also: TCT 2020 | Fewer Symptoms and Events when Optimizing with iFR.


The study population was divided into three groups: revascularization with FFR ≤0.80; deferred lesions according to negative concordant FFR and iFR, and deferred lesions with discordant FFR and iFR results.

The rates of combined events (cardiac death, vessel-related infarction, and ischemia-driven revascularization) at 5 years were 14.8%, 7.5%, and 14.4% for revascularized patients, concordant deferred patients, and discordant deferred patients, respectively.

Results show a similar prognosis for concordant positive values (≤0.89 or ≤0.80 for iFR or FFR, respectively).

The group of patients deferred with discordant values showed more events than the concordant deferred group. However, these events were less than the number of events in the revascularization group. Deferring based on any index is a reasonable option. Conversely, choosing revascularization does not worsen patient prognosis.

JAHA-120-016818

Original Title: Long-Term Clinical Outcomes of Nonhyperemic Pressure Ratios: Resting Full-Cycle Ratio, Diastolic Pressure Ratio, and Instantaneous Wave-Free Ratio.

Reference: Joo Myung Lee et al. J Am Heart Assoc. 2020;9:e016818. DOI: 10.1161/JAHA.120.016818.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...